Benuvia Operations, LLC.
Matt Delaney serves as the Chief Business Development Officer at Benuvia Operations, LLC, since June 2024. Prior to this role, Delaney held various leadership positions in business development within the life sciences sector, including Vice President roles at Exela Pharma Sciences LLC and Cytovance Biologics. Delaney's extensive experience encompasses significant contributions to Contract Development and Manufacturing Organizations (CDMOs) and Clinical Research Organizations (CROs), working at notable companies such as Lake Pharma (now Curia), Nitto Denko Avecia Inc., Pharm-Olam (now Allucent), and Datatrak International. Delaney's educational background includes an MBA from San Diego State University, with additional certifications in International Business and Finance from Western International University.
This person is not in any offices
Benuvia Operations, LLC.
Benuvia Manufacturing is a leading developer and manufacturer of high-purity, pharmaceutical cannabinoid ingredients and products. We offer a comprehensive suite of solutions for pharmaceutical, biotechnology, and consumer product companies to achieve their development and commercial needs. We have over 100,000 square feet of state-of-the-art research, development and manufacturing space across two cGMP facilities in Chandler, Arizona and Round Rock, Texas. We began manufacturing pharmaceutical grade cGMP pure quality cannabidiol (CBD) in 2009 and our Round Rock facility has produced CBD since 2014 (DMF 32552). Today, Round Rock is the only CBD active pharmaceutical ingredient (API) contract manufacturing site in the U.S. producing an FDA approved cannabinoid drug (SYNDROS®). Our facilities are DEA and FDA registered cGMP production sites and are fully regulated and compliant with all DEA, EPA, and OSHA requirements. Further information is available at www.benuviamanufacturing.com.